Medtronic self-expanding TAVR platform shows excellent longer-term performance at five years in SURTAVI Trial

Rhea-AI Summary

Medtronic (NYSE:MDT) announced positive five-year clinical results from the SURTAVI Trial for TAVR patients at intermediate risk. The trial revealed that TAVR with the CoreValve and Evolut platforms demonstrated comparable all-cause mortality rates (30.0% for TAVR vs. 28.7% for SAVR) and lower mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg), ensuring valve performance and safety. The study included 864 TAVR patients compared to 796 surgical patients, highlighting the long-term viability of TAVR in treating severe aortic stenosis.

Positive

• Five-year outcomes show TAVR maintains hemodynamic benefits.
• TAVR mortality rates at five years (30.0%) are comparable to surgical valve replacement (28.7%).
• Lower mean aortic valve gradient (8.6 mm Hg) at five years indicates excellent valve performance.

Negative

• None.

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years

DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33^rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Data from the trial showed that the hemodynamic (blood flow) benefits of the Medtronic CoreValve™ and Evolut™ platforms were maintained at five years with an excellent safety profile and stable valve performance in patients with symptomatic, severe aortic stenosis who are at an intermediate risk for open-heart surgery.

At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement (SAVR) (30.0% for TAVR versus 28.7% for SAVR; p=0.55), while rates of disabling stroke were also similar (4.1% for TAVR versus 5.8% for SAVR, p = 0.12). The TAVR arm continued to demonstrate durable valve longevity, as evidenced by better mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg; p<0.001) at five years. Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR.

In the study, patients considered to be at intermediate risk for open-heart surgery had a risk of mortality of ≥ 3 and < 15% at 30 days following the procedure in combination with other factors.

"TAVR has revolutionized the treatment of aortic stenosis with more TAVR cases now performed than surgical aortic valve replacement for this disease. With this shift in treatment, longer-term, randomized data is increasingly important as we strive to better understand the lifetime management of these patients," said Michael Reardon, M.D., professor of cardiothoracic surgery and Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist DeBakey Heart & Vascular Center, principal investigator in the SURTAVI trial.

The global, prospective, multi-center, randomized SURTAVI Trial evaluated two early valve generations (CoreValve™, Evolut™ R) across a variety of valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients. Patients in the TAVR arm were compared to 796 intermediate-risk patients who were randomized to open-heart surgery.

"These longer-term outcomes are remarkably similar after TAVR and surgery in patients with severe aortic stenosis at intermediate operative risk," said Nicolas Van Mieghem, M.D., Ph.D., professor of interventional cardiology, department of cardiology, Thoraxcenter, Erasmus University Medical Center in Rotterdam, The Netherlands, who presented the data at the meeting. "Additionally, results from this study are particularly impressive given the TAVR devices evaluated were first- and second-generation systems."

The Evolut TAVR platform, which includes the Evolut™ R, Evolut™ PRO, Evolut™ PRO+, and newest-generation Evolut™ FX valves, is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low) in the U.S.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, cranial and spinal robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Joey Lomicky	Ryan Weispfenning
Public Relations	Investor Relations
+1-763-526-2494	+1-763-505-4626

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-self-expanding-tavr-platform-shows-excellent-longer-term-performance-at-five-years-in-surtavi-trial-301417401.html

SOURCE Medtronic plc

FAQ

What were the key findings from Medtronic's SURTAVI Trial presented at TCT 2021?

The SURTAVI Trial showed that TAVR with Medtronic's CoreValve and Evolut platforms maintains hemodynamic benefits and comparable mortality rates to surgical valve replacement after five years.

What is the mortality rate for TAVR patients after five years according to the SURTAVI Trial?

The five-year all-cause mortality rate for TAVR patients in the SURTAVI Trial was 30.0%, which is similar to 28.7% for surgical aortic valve replacement.

How does TAVR performance compare to SAVR in the SURTAVI Trial?

TAVR demonstrated better mean aortic valve gradients (8.6 mm Hg) compared to SAVR (11.2 mm Hg) at five years, indicating better valve performance.

What is the significance of the SURTAVI Trial results for intermediate-risk patients?

The results highlight the long-term safety and effectiveness of TAVR for intermediate-risk patients with severe aortic stenosis, reinforcing its role in treatment options.